-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, LU9Z8UaYuSDAfqNQh5QWoFFr8UsHaxDR57li0D9c28MaQtgKmqeTvJL6sVDBATCz M512lP6L5N2S5pQ6SIpW9g== 0001125282-03-003755.txt : 20030605 0001125282-03-003755.hdr.sgml : 20030605 20030605151428 ACCESSION NUMBER: 0001125282-03-003755 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20030603 ITEM INFORMATION: Regulation FD Disclosure FILED AS OF DATE: 20030605 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PALL CORP CENTRAL INDEX KEY: 0000075829 STANDARD INDUSTRIAL CLASSIFICATION: GENERAL INDUSTRIAL MACHINERY & EQUIPMENT, NEC [3569] IRS NUMBER: 111541330 STATE OF INCORPORATION: NY FISCAL YEAR END: 0731 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-04311 FILM NUMBER: 03734067 BUSINESS ADDRESS: STREET 1: 2200 NORTHERN BLVD CITY: EAST HILLS STATE: NY ZIP: 11548 BUSINESS PHONE: 5164845400 MAIL ADDRESS: STREET 1: 2200 NORTHERN BLVD CITY: EAST HILLS STATE: NY ZIP: 11548 8-K 1 b325302_8k.htm INITIAL FILING - CURRENT REPORT Prepared and filed by St Ives Burrups

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): June 3, 2003

PALL CORPORATION
(Exact name of registrant as specified in its charter)

New York
(State or other jurisdiction
of incorporation)
1- 4311
(Commission file number)
11-1541330
(I.R.S. Employer
Identification No.)
     
2200 Northern Boulevard, East Hills, NY
(Address of principal executive offices)
11548
(Zip Code)
     
(516) 484-5400
(Registrant’s telephone number, including area code)

    


ITEM 9. Information Provided Under Item 12 (Results of Operations and Financial Condition)

The following information is furnished pursuant to Item 12, “Results of Operations and Financial Condition.”

On June 3, 2003, Pall Corporation issued a press release announcing its financial results for the fiscal quarter ended May 3, 2003. A copy of the press release is furnished as Exhibit 99.1 to this report.

 

2


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

       Pall Corporation
       
June 5, 2003
/s/ JOHN ADAMOVICH, JR
John Adamovich, Jr
Chief Financial Officer
and Treasurer

3


INDEX TO EXHIBITS

 

Exhibit    
Number   Description
99.1
  Press release, dated June 3, 2003, issued by Pall Corporation

4


EX-99.1 3 b325302_ex99-1.htm THIRD QUARTER SALES AND EARNINGS Prepared and filed by St Ives Burrups

EXHIBIT 99.1

Pall Corporation Third Quarter Sales and Earnings Surge

East Hills, NY (June 03, 2003)—Pall Corporation (NYSE: PLL) today reported sales and earnings results for the third quarter and nine months of fiscal 2003, which ended May 3, 2003.

Sales for the third quarter increased 39½% to $421.5 million compared with $302.4 million last year. Foreign exchange rates increased sales 12% or $36.6 million. Earnings increased nearly 70% and were $44.6 million, or 36 cents per share, excluding restructuring and other charges, compared to last year’s $26.4 million, or 21 cents per share. Reported earnings for the third quarter were $40.4 million, or 33 cents per share.

Sales for the nine months increased 32½% to $1.142 billion compared to $861.9 million last year. Foreign exchange rates increased sales 8% or $68.1 million. Earnings were $92.8 million, or 75 cents per share, excluding restructuring and other charges, compared to last year’s $64.3 million, or 52 cents per share. Restructuring and other charges of $46.4 million, or 36 cents per share (including the pro forma tax effect), were recorded in the nine months primarily to write-off the in-process research and development from the acquired Filtration and Separations Group (“FSG”). This reduced the reported results for the nine months to earnings of $48.6 million, or 39 cents per share.

Eric Krasnoff, Pall’s Chairman and CEO, said, “We are pleased to have produced another solid quarter. Sales increased 39½%. Earnings and earnings per share each increased nearly 70%. Our results exceeded analyst consensus estimates. Cash flow for the nine months was strong and net debt has been reduced by $63 million.

The first nine months of the fiscal year have seen substantial progress on our three main goals. Those are to improve profitability, to aggressively reduce debt and to successfully integrate FSG into Pall. We are well ahead of our targets in each of these areas.

The end of April marked our first anniversary as the “new Pall” with FSG now fully integrated into our sales, marketing and technical organizations. We are selling more to shared and new customers than we could have alone. As important, operating margins have improved to 19.8% from 16.9% in the third quarter last year.

Among the highlights for the quarter:

All Industrial business segments experienced double-digit sales growth in the quarter ranging from 25½ to 57%. In total, Industrial sales were up 47%. Operating profit improved 114% to $43.7 million. The General Industrial segment, which serves industries including food and beverage, water processing and chemicals, achieved sales growth of 57%. Microelectronics posted its fourth consecutive quarter of double-digit sales growth in a semiconductor market that is slowly recovering. Aerospace also turned in a double-digit increase in sales as Military Aerospace sales increased 55%. Commercial Aerospace held steady in the quarter.

Turning to Life Sciences, BioPharmaceuticals grew 16½% compared to last year's third quarter, buoyed by strong biotechnology sales. Medical sales increased 6% sequentially over the second quarter but were flat compared to the same quarter last year. Blood filter sales were down 1½% compared to last year as we continue to focus on improving margins. Third quarter Medical profits came in at 19.5%, building on the pattern of sequential operating profit improvement that began with 7.8% in the first quarter.

By region, Europe posted sales growth of 39%, Asia’s sales grew by 36½% and Western Hemisphere sales were up by 15% compared to last year's third quarter. With sales growth of $33 million in the quarter compared to our second quarter, operating margins in each geography have improved considerably.”

Commenting on the quarter’s earnings growth compared to last year, Mr. Krasnoff said, “The 15 cent improvement in earnings per share is attributable to organic growth, aided by continuing cost reduction programs, FSG synergies and also includes about 4 cents per share for foreign exchange translation. Our estimate of $7 million in acquisition-related synergies for this quarter indicates that full year synergies continue to run ahead of our goal.”

1


Looking ahead, Mr. Krasnoff continued, “We anticipate earnings per share for the year in the range of $1.14 to $1.19. The midpoint of this range is an increase of 9 cents per share from the midpoint of our prior guidance range and, if achieved, represents a 42% increase from the prior year's 82 cents per share.”

Tomorrow, June 4, 2003, at 8:30 a.m. EST, Pall Corporation will host its quarterly earnings conference call. Individuals can access the webcast on the home page of the Company’s website, www.pall.com. Listening to the webcast requires speakers and Microsoft Windows Media Player audio software. The webcast will be archived for 14 days.

Pall Corporation is the global leader in the rapidly growing field of filtration, separations and purification. Pall's business is organized around two broad markets: Life Sciences and Industrial. The Company provides leading-edge products to meet the demanding needs of customers in biotechnology, pharmaceuticals, transfusion medicine, semiconductors, municipal drinking water and aerospace. Total revenues in the last twelve months were about $1.5 billion. The Company is headquartered in East Hills, New York. Further information can be found on its Web site www.pall.com.

This release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current Company expectations and are subject to risks and uncertainties, which could cause actual results to differ materially. Such risks and uncertainties include, but are not limited to: fluctuations in foreign currency exchange rates; regulatory approval and market acceptance of new technologies; changes in product mix and product pricing and in interest rates and cost of raw materials; the Company’s success in enforcing its patents and protecting its proprietary products and manufacturing techniques; global and regional economic conditions and legislative, regulatory and political developments; and domestic and international competition in the Company’s global markets. Additional information regarding these and other factors is available on the web at www.pall.com and is included in the Company’s reports filed with the U.S. Securities and Exchange Commission. Copies of such reports can be obtained, without charge, at: www.sec.gov.

Financial Tables to Follow...

2


PALL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands)

     
  MAY 3,
2003
AUG. 3,
2002
 
Assets  

 

 
               
Cash and short-term investments   $ 148,763   $ 145,424  
Accounts receivable, net     394,166     415,853  
Inventories, net     293,529     256,910  
Other current assets     106,960     94,947  
   

 

             
Total current assets
    943,418     913,134  
             
Property, plant and equipment, net     597,993     605,095  
Other assets     486,436     492,214  
   

 

             
Total assets
  $ 2,027,847   $ 2,010,443  
   

 

             
Liabilities and Stockholders’ Equity              
             
Short-term debt   $ 57,626   $ 103,546  
Accounts payable, income taxes              
and other current liabilities
    332,604     331,777  
   

 

             
Total current liabilities
    390,230     435,323  
             
Long-term debt     606,139     619,705  
Deferred taxes and other              
non-current liabilities
    142,673     135,695  
   

 

             
Total liabilities
    1,139,042     1,190,723  
             
Stockholders’ equity     888,805     819,720  
   

 

             
Total liabilities and              
stockholders’ equity
  $ 2,027,847   $ 2,010,443  
   

 

 

3


PALL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS
(Amounts in thousands except per share data)

     
THIRD QUARTER ENDED
NINE MONTHS ENDED
 
   

 

 
     
MAY 3,
2003
APR. 27,
2002
MAY 3,
2003
APR. 27,
2002
 
   

 

 

 

 
                           
Net sales   $ 421,491   $ 302,377   $ 1,142,223   $ 861,931  
Cost of sales     205,587     145,482     579,933     425,946  
   

 

 

 

 
Gross profit     215,904     156,895     562,290     435,985  
                           
Selling, general and                          
administrative expenses
    138,664     107,245     384,361     306,471  
Research and development     14,255     13,159     39,715     38,474  
Restructuring and other charges     5,036    
    46,335    
 
 
                         
Interest expense, net     5,765     2,590     19,238     8,668  
   

 

 

 

 
                           
Earnings before income taxes     52,184     33,901     72,641     82,372  
                         
Provision for income taxes     11,829     7,458     24,045     18,122  
   

 

 

 

 
                           
Net earnings   $ 40,355   $ 26,443   $ 48,596   $ 64,250  
   

 

 

 

 
                           
Earnings per share:                          
Basic:
  $ 0.33   $ 0.22   $ 0.40   $ 0.53  
   

 

 

 

 
Diluted:
  $ 0.33   $ 0.21   $ 0.39   $ 0.52  
   

 

 

 

 
Average number of                          
shares outstanding:
                         
Basic:
    123,146     122,336     122,983     122,242  
Diluted
    123,891     123,512     123,745     123,478  
                           
Net earnings as reported   $ 40,355   $ 26,443   $ 48,596   $ 64,250  
Restructuring and other                          
charges after pro forma tax effect
    4,277  (a)  
 –
   
44,205
 (a)
 
 
   

 

 

 

 
                           
Pro forma earnings   $ 44,632   $ 26,443   $ 92,801   $ 64,250  
   

 

 

 

 
                           
Diluted earnings per                          
share as reported
 
$
0.33
 
$
0.21
 
$
0.39
 
$
0.52
 
                           
Restructuring and                          
other charges
 
$
0.03
 (a)
$
  $
0.36
(a)
$
 
   

 

 

 

 
Pro forma diluted                          
earnings per share
  $ 0.36   $ 0.21   $ 0.75   $ 0.52  
   

 

 

 

 

(a) Restructuring and other charges for the nine months includes $37,600 (30 cents per share) of acquired in-process research and development and $8,735 (6 cents per share, after pro forma tax effect) of restructuring costs inclusive of $5,036 (3 cents per share, after pro forma tax effect) incurred in the third quarter.

4


PALL CORPORATION MARKET SEGMENT AND GEOGRAPHIC INFORMATION
(DOLLAR AMOUNTS IN THOUSANDS)

                       
% CHANGE
 
SALES                
%
   
IN LOCAL
 
THIRD QUARTER ENDED:    
MAY 3, 2003
APR. 27, 2002
CHANGE
CURRENCY
 

 

 

 

 

 
MARKET SEGMENT                          
INFORMATION:                          
                           
Medical (a)   $ 83,985   $ 79,075     6      
BioPharmaceuticals (a)     93,295     73,093     27 ½   16 ½
   

 

             
Total Life Sciences     177,280     152,168     16 ½   8  
 



       
                 
General Industrial     150,050     84,351     78     57  
Aerospace     51,060     38,454     33     25 ½
Microelectronics     43,101     27,404     57 ½   46  
 



       
Total Industrial     244,211     150,209     62 ½   47  
 



       
                 
Total   $ 421,491   $ 302,377     39 ½   27 ½
 



       
                 
GEOGRAPHIC                          
INFORMATION:                          
                 
SALES                          
TO UNAFFILIATED CUSTOMERS                          
                 
Western Hemisphere
  $ 164,410   $ 141,829     16     15  
Europe     178,536     107,328     66 ½   39  
Asia     78,545     53,220     47 ½   36 ½
 



       
                 
Total   $ 421,491   $ 302,377     39 ½   27 ½
 



       
                 
TOTAL SALES                          
Western Hemisphere
  $ 206,492   $ 172,721              
Europe     202,241     123,853              
Asia     79,680    
53,609
             
Eliminations     (66,922 )   (47,806 )            
 



       
Total   $ 421,491   $ 302,377              
 



       

(a) Certain prior year amounts have been reclassified to conform to the current year presentation.

5


OPERATING PROFIT                          
THIRD QUARTER ENDED:    
MAY 3, 2003
   
%
   
APR. 27, 2002
   
%
 

 

 

 

 

 
MARKET SEGMENT                          
INFORMATION:                          
                           
Medical (a)   $ 16,413     19.5   $ 12,370     15.6  
BioPharmaceuticals (a)     23,269     24.9     18,290     25.0  
 

   

   
Total Life Sciences     39,682     22.4     30,660     20.1  
 

   

   
                 
General Industrial     19,582     13.1     9,042     10.7  
Aerospace     16,354     32.0     8,961     23.3  
Microelectronics     7,761     18.0     2,416     8.8  
 

   

   
Total Industrial     43,697     17.9     20,419     13.6  
 

   

   
Subtotal
    83,379     19.8     51,079     16.9  
Restructuring and other charges     (5,036 )                
General corporate expenses     (20,394 )         (14,588 )      
Interest expense, net     (5,765 )         (2,590 )      
 

   

   
Earnings before income taxes   $ 52,184         $ 33,901        
 

   

   
                 
GEOGRAPHIC INFORMATION:                          
                 
Western Hemisphere   $ 31,801     15.4   $ 19,981     11.6  
Europe     36,996     18.3     22,956     18.5  
Asia     13,858     17.4     8,607     16.1  
Eliminations     724          
(465
)      
 

   

   
Subtotal
    83,379     19.8     51,079     16.9  
Restructuring and other charges     (5,036 )                  
General corporate expenses     (20,394 )         (14,588 )      
Interest expense, net     (5,765 )         (2,590 )      
 

   

   
Earnings before income taxes   $ 52,184         $ 33,901        
 

   

   

(a) Certain prior year amounts have been reclassified to conform to the current year presentation.

6


PALL CORPORATION MARKET SEGMENT AND GEOGRAPHIC INFORMATION
(DOLLAR AMOUNTS IN THOUSANDS)

     
% CHANGE
SALES    
%
IN LOCAL
NINE MONTHS ENDED:    
MAY 3, 2003
APR. 27, 2002
CHANGE
CURRENCY

 

 

 

 

 
MARKET SEGMENT                          
INFORMATION:                          
                           
Medical (a)   $ 221,070   $ 219,243     1     (3 ½)
BioPharmaceuticals (a)     249,010     205,967     21     13 ½
 



       
Total Life Sciences     470,080     425,210     10 ½   4 ½
 



       
                 
General Industrial     417,317     245,046     70 ½   57 ½
Aerospace     134,032     114,836     16 ½   11 ½
Microelectronics     120,794     76,839     57     49 ½
 



       
Total Industrial     672,143     436,721     54     44  
 



       
                 
Total   $ 1,142,223   $ 861,931     32 ½   24 ½
 



       
                 
GEOGRAPHIC INFORMATION:                          
                 
SALES                          
TO UNAFFILIATED CUSTOMERS                          
                 
Western Hemisphere
  $ 453,569   $ 393,841     15     16  
Europe     479,556     307,348     56     36  
Asia     209,098     160,742     30     24  
 



       
                 
Total   $ 1,142,223   $ 861,931     32 ½   24 ½
 



       
                 
TOTAL SALES                          
                           
Western Hemisphere
  $ 573,848   $ 479,596              
Europe     541,140     350,238              
Asia     211,953     162,097              
Eliminations     (184,718 )   (130,000 )            
   

 

             
                 
Total   $ 1,142,223   $ 861,931              
 



       

(a) Certain prior year amounts have been reclassified to conform to the current year presentation.

7


OPERATING PROFIT                          
NINE MONTHS ENDED:    
MAY 3, 2003
%
APR. 27, 2002
%
 

 

   
 

 

 
MARKET SEGMENT                          
INFORMATION:                          
                           
Medical (a)   $ 33,605     15.2   $ 28,566     13.0  
BioPharmaceuticals (a)     54,480     21.9     51,558     25.0  
 

   

   
Life Sciences     88,085     18.7     80,124     18.8  
 

   

   
                 
General Industrial     44,619     10.7     25,338     10.3  
Aerospace     37,593     28.0     27,672     24.1  
Microelectronics     19,821     16.4     2,560     3.3  
   

       

       
Industrial     102,033     15.2     55,570     12.7  
   

       

       
Subtotal
    190,118     16.6     135,694     15.7  
Restructuring and other charges     (46,335 )                
General corporate expenses     (51,904 )         (44,654 )      
Interest expense, net     (19,238 )         (8,668 )      
 

   

   
Earnings before income taxes   $ 72,641         $ 82,372        
 

   

   
                 
GEOGRAPHIC INFORMATION:                          
                 
Western Hemisphere   $ 76,477     13.3   $ 51,564     10.8  
Europe     83,994     15.5     57,640     16.5  
Asia     31,509     14.9     26,174     16.1  
Eliminations     (1,862 )        
316
       
 

   

   
Subtotal
    190,118     16.6     135,694     15.7  
Restructuring and other charges     (46,335 )                
General corporate expenses     (51,904 )         (44,654 )      
Interest expense, net     (19,238 )         (8,668 )      
 

   

   
Earnings before income taxes   $ 72,641         $ 82,372        
 

   

   

(a) Certain prior year amounts have been reclassified to conform to the current year presentation.

Contact:

John Adamovich,
Pall Corporation
Tel: (516) 801-9808

###

 

8


-----END PRIVACY-ENHANCED MESSAGE-----